Becker's Healthcare September 12, 2024
Claire Wallace

The FDA has approved Johnson & Johnson’s Tremfya to treat adults with moderate to severe ulcerative colitis.

It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, which is a driver...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
What A Potential FDA Red Dye No. 3 Ban Could Mean For Public Health
STAT+: Former Trump FDA, CMS heads lay out how his return could reshape health policy
The Overdue Imperative Of Cross-Racial Pulse Oximeters
FDA’s evolving regulatory framework for AI use in drug & device clinical trials and research
FDA has approved over 1,000 clinical AI applications, with most aimed at radiology

Share This Article